The global biosimilar market is undergoing a period of significant expansion, with projections indicating a robust growth from US34.8 billion in 2024 to an estimated US93.1 billion by 2030, reflecting a compound annual growth rate (CAGR) of 17.8%.1 This substantial market acceleration is primarily driven by the escalating costs of originator biologic drugs and the increasing global demand for more affordable therapeutic alternatives.1 Biosimilars offer considerable potential for cost savings, with estimates suggesting over $180 billion in savings for the US healthcare system within the next five years.4 This financial relief translates directly into enhanced patient access to critical, often life-saving, treatments that might otherwise be prohibitively expensive.2
However, the entry of these cost-effective alternatives into the market is frequently hindered by the intricate and extensive patent landscapes maintained by originator companies, often characterized by dense “patent thickets”.4 These robust patent protections are crucial for originator companies to recoup their substantial research and development (R&D) investments, which can often exceed billions of dollars.10 Consequently, patent litigation is not merely a peripheral legal process but an inevitable and central component of the biosimilar market, directly influencing market entry timelines and competitive dynamics.10
The outcomes of biosimilar patent litigation are shaped by a confluence of factors, including the distinct regulatory frameworks in various jurisdictions, such as the Biologics Price Competition and Innovation Act (BPCIA) in the United States and the European Medicines Agency (EMA) guidelines in Europe.13 The specific types of patents asserted by originators play a crucial role, with active pharmaceutical ingredient (API), composition, and treatment patents correlating with longer market launch delays, despite manufacturing patents being the most frequently asserted.7 Strategic maneuvers employed by both originator companies and biosimilar developers, including the optional “patent dance” under the BPCIA, significantly influence the trajectory and resolution of disputes.2 The Patent Trial and Appeal Board (PTAB) has emerged as a powerful, faster, and more cost-effective forum for challenging patent validity, profoundly impacting litigation strategies and the likelihood of preliminary injunctions.2 Settlements are a predominant outcome in BPCIA litigation, often resulting in earlier market entry for biosimilars compared to protracted full trials.17
II. Introduction to Biosimilars and the Regulatory Landscape
A. Defining Biosimilars and Distinguishing from Generics
Biosimilars represent a class of biological drugs that are highly similar to an already approved reference biological drug.19 Unlike generic drugs, which are typically synthesized from chemicals and have simple, identical structures, biosimilars are complex molecules derived from living organisms, such as living cells, bacteria, or yeast.21 This fundamental difference in origin and complexity means that while generic drugs are exact copies of their brand-name counterparts, biosimilars are “highly similar” but not identical to their reference products due to inherent natural variability in biological systems and manufacturing processes.20
The regulatory pathways for biosimilars reflect this complexity. Generic drugs demonstrate bioequivalence to the brand-name drug, allowing them to avoid costly clinical trials.21 In contrast, biosimilar manufacturers must demonstrate that their product is highly similar to the reference product, with no clinically meaningful differences in terms of safety, purity, and potency.21 This requires a comprehensive comparability exercise involving detailed analytical, nonclinical, and clinical studies.13 Despite these rigorous requirements, the abbreviated approval pathways for biosimilars still aim to reduce the need for unnecessary repetition of extensive clinical trials already conducted for the reference medicine, potentially leading to faster market access and reduced costs.23
B. Overview of Regulatory Pathways (US and EU)
The regulatory frameworks in the United States and Europe have established distinct yet evolving pathways for biosimilar approval.
1. United States (FDA and BPCIA)
In the U.S., the Biologics Price Competition and Innovation Act (BPCIA), enacted in 2010 as part of the Affordable Care Act, created an abbreviated licensure pathway for biosimilar and interchangeable biological products.27 This pathway, under Section 351(k) of the Public Health Services Act, allows biosimilar manufacturers to demonstrate “biosimilarity” to a reference product rather than conducting entirely new, comprehensive clinical trials.2 The goal of a biosimilar development program is to demonstrate this biosimilarity, not to independently establish the safety and effectiveness of the proposed product from scratch.25 This often means fewer expensive and lengthy clinical trials for biosimilar manufacturers, potentially accelerating access and reducing costs.25
For a biosimilar to be approved, its manufacturer must submit an abbreviated Biologics License Application (aBLA) containing data from analytical studies, animal studies (if necessary), and clinical studies sufficient to demonstrate safety, purity, and potency in one or more indications for which the reference product is licensed.25 This typically includes assessing immunogenicity, pharmacokinetics (PK), and sometimes pharmacodynamics (PD), and may involve a comparative clinical study.25 The FDA reviews the totality of the data in a stepwise fashion, starting with detailed analytical characterization.25
An additional, higher standard exists for “interchangeable biosimilar products.” To be designated as interchangeable, a biosimilar must meet further requirements, including demonstrating that it is expected to produce the same clinical result as the reference product in any given patient, and that switching between the proposed interchangeable product and the reference product does not increase safety risks or decrease effectiveness.25 While federal law grants the FDA authority for interchangeability, state laws govern pharmacy-level substitution, often requiring an FDA interchangeability designation as a prerequisite for substitution without prescriber intervention.22 The first interchangeable biosimilar, an insulin product, was approved in July 2021.29
2. European Union (EMA)
The European Medicines Agency (EMA) has been a pioneer in biosimilar regulation, approving the first biosimilar in 2006.20 The EMA is responsible for evaluating most applications to market biosimilars in the EU, ensuring they meet the same standards of pharmaceutical quality, safety, and efficacy as all biological medicines.20 The EU’s regulatory framework, established in 2004, aims to balance rigorous evaluation with fostering competition and improving patient access.30
The EMA’s approach is founded on the scientific principle that a biological molecule’s structure determines its function.30 Therefore, if a biosimilar candidate can be shown through state-of-the-art analytical methods to be highly similar to its reference medicinal product (RMP) in all critical quality attributes (CQAs), and if comparable PK profiles are demonstrated, then clinical efficacy and safety can often be inferred.30 This “tailored clinical approach” may, under specific prerequisites, be sufficient for biosimilar approval, potentially waiving the need for comparative efficacy studies and thus reducing development costs and accelerating market timelines.30 These prerequisites include a well-understood mechanism of action (MoA) for the biosimilar, identification and characterization of all functionally relevant CQAs, and robust analytical comparability data from a sufficient quantity of RMP and biosimilar batches.30
The EMA and the Heads of Medicines Agencies (HMA) have emphasized that EU-approved biosimilars are interchangeable from a scientific viewpoint, meaning they can be used interchangeably with their reference product or other biosimilars of the same reference product, provided product information is carefully considered.20 Safety data from over 1 million patient-treatment years support the safety and interchangeability of EMA-approved biosimilars.20
III. The Biologics Price Competition and Innovation Act (BPCIA) and US Patent Litigation
A. Purpose and Framework of the BPCIA
The Biologics Price Competition and Innovation Act (BPCIA) was enacted on March 23, 2010, as part of the Patient Protection and Affordable Care Act.27 Its primary purpose is to create an abbreviated licensure pathway for biosimilar and interchangeable biological products, thereby promoting competition and innovation in the biologics market.28 The BPCIA is often referred to as the “biosimilar pathway” and is modeled after the Hatch-Waxman Act, which established a similar pathway for generic, small-molecule pharmaceuticals.2 This legislative design reflects a clear intent to ignite competition and drive down the price of complex biologic drugs, much as Hatch-Waxman did for small-molecule generics.2 The BPCIA aims to strike a balance between encouraging the approval and market entry of lower-cost biosimilars and providing exclusivity incentives for the research and development of pioneer medicines.27
The BPCIA framework includes specific regulatory exclusivities: a biosimilar application (351(k) application) cannot be filed for four years after the reference product’s initial license date, and the approval of a biosimilar cannot become effective until 12 years have passed from the reference product’s first approval.2 This provides originators with a defined window of market exclusivity to ensure a return on their significant R&D investments.2
B. The “Patent Dance” and Litigation Phases
The BPCIA establishes a complex patent litigation framework, colloquially known as the “patent dance,” designed to facilitate the exchange of information between innovator biologics manufacturers (Reference Product Sponsors, RPSs) and biosimilar applicants (BAs).2 This structured information exchange aims to resolve patent disputes early and narrow the scope of potential litigation.2
1. Optionality and Information Exchange
The Supreme Court’s landmark 2017 decision in Sandoz Inc. v. Amgen Inc. fundamentally reshaped the biosimilar patent dance by confirming its optionality.2 While the BPCIA states that an applicant “must” provide its application and manufacturing information, the statute also provides a remedy for an applicant’s failure to do so.32 If a biosimilar applicant chooses not to engage in the patent dance, the patent owner’s only recourse is to initiate a patent infringement lawsuit, and the RPS cannot compel the biosimilar applicant’s participation in the information exchange.2 However, engaging in the dance offers strategic advantages for both sides.17
The patent dance is triggered when the biosimilar applicant notifies the RPS that the FDA has accepted its aBLA, providing a copy of the aBLA and “other manufacturing information” within 20 days of acceptance.17 This initiates a series of information exchanges. Within 60 days of receiving this information, the RPS must provide the biosimilar applicant with a list of patents for which it believes it could assert an infringement claim.2 The RPS must also identify any patents on this list that it would be prepared to license.2 A critical consequence for the RPS is that failure to timely list a patent on this initial exchange generally precludes them from suing the biosimilar applicant on that patent until the biosimilar product is commercially marketed.2 This compels originators to be prepared with their patent lists well in advance of an aBLA filing.2
The biosimilar applicant then has another 60 days to respond, which may include their own list of patents that they believe the RPS could reasonably assert (if omitted by the RPS).2 Crucially, for each patent identified by either party, the biosimilar applicant must provide a detailed, claim-by-claim statement outlining the factual and legal bases for any assertions of invalidity, unenforceability, or non-infringement.2 This structured information exchange addresses the information asymmetry between the RPS and the biosimilar applicant, as the RPS initially holds the patent rights but lacks detailed knowledge of the biosimilar product and its manufacturing process.2 The fixed deadlines and detailed disclosure requirements create a strategic chess match where the precision and quality of information exchanged can significantly influence subsequent litigation.2
2. Two Phases of Litigation
The BPCIA framework allows for two phases of litigation.17
Phase 1 (First Wave): This initial phase is triggered when the parties attempt to agree on a subset of patents for immediate litigation.2 If an agreement cannot be reached within 15 days, the biosimilar applicant informs the RPS of the number of patents they will litigate, and both parties then exchange their respective lists for immediate court action.2 The RPS is then obligated to bring an action for patent infringement within 30 days for each implicated patent.2 The filing of the aBLA itself is considered an artificial act of infringement for these patents, enabling pre-market litigation.2 The idea behind this phase is to address the most important patents while the biosimilar application is still under FDA review, potentially resolving the lawsuit by litigating only a small subset of patents, rather than the RPS’s entire portfolio, which can sometimes number in the hundreds.17
Phase 2 (Second Wave): The second phase of litigation is triggered by the biosimilar’s notice of commercial marketing.17 The BPCIA requires that a biosimilar applicant “shall provide notice to the reference product sponsor not later than 180 days before the date of the first commercial marketing of the biological product licensed under subsection (k)”.32 During this second wave, the brand drug company is free to assert patents that the biosimilar firm did not agree to include during the patent dance.33 At this time, the branded drug company can also request a preliminary injunction to stop the biosimilar from manufacturing or selling its product, aiming to maintain market exclusivity until the completion of patent litigation.4 Only after both waves of litigation are resolved will the biosimilar firm know if it can launch its product free from patent risk.33
Non-compliance with the patent dance can have significant implications for biosimilar applicants and innovator biologics manufacturers, potentially leading to declaratory judgment actions, injunctions, and damages.28 If an applicant fails to provide its application and manufacturing information, the RPS may immediately bring an action for a declaration of infringement, validity, or enforceability of any patent that claims the biological product or its use.32 This means the biosimilar applicant loses the “substantial control” over litigation timing and scope that the patent dance would otherwise provide.34
C. Types of Patents Asserted and Impact on Market Delays
In biosimilar litigation, various types of patents are asserted by originator companies to protect their intellectual property. These can include patents covering the active pharmaceutical ingredient (API), composition of matter, manufacturing processes, treatment methods, and even the devices used to administer the drug.4
A study investigating the reasons behind biosimilar market delays found that while manufacturing patents are the most common type referenced in litigation, other patent types have a greater impact on market launch delays.7 Specifically, a higher proportion of composition, API, and treatment patents correlated with longer market launch delays.7 Conversely, a higher proportion of manufacturing patents was associated with shorter market launch delays.7 This challenges the prior belief that secondary manufacturing patents, often filed after the originator drug’s approval, were the primary cause of delays due to the complexity of biologic manufacturing and the extensive patent portfolios built by originators.7 The study’s findings suggest that patents related to the core active ingredient, the drug’s formulation, and its therapeutic uses appear to be more strongly associated with prolonged delays in biosimilar market entry.7
IV. Patent Litigation in Europe, Canada, and Japan
Patent litigation strategies and outcomes for biosimilars vary significantly across different global jurisdictions, reflecting diverse regulatory frameworks and legal precedents.
A. Europe
In Europe, the European Medicines Agency (EMA) has established a robust regulatory framework for biosimilar approval.13 A key finding from European analyses is that secondary patents have generally failed to stop biosimilar competition.35 While pharmaceutical corporations routinely seek secondary patents for minor modifications to drugs to extend exclusivity, a study of biosimilar litigation in Europe found that these secondary patents were not sufficient to delay the market entry of biosimilars for nine top-selling monoclonal antibodies.35
The main hurdle preventing biosimilars from coming to market in Europe has been the primary patent on the originator product, along with supplementary protection certificates (SPCs) and pediatric extensions, which provide an average effective market protection of 10 to 17 years.35 Despite innovators’ efforts to extend exclusivity by patenting variations in formulation, new dosage regimens, routes of administration, and combination therapies, or by developing next-generation products, many secondary patents were either not upheld by the European Patent Office or were successfully challenged by competitors in court.35 For example, biosimilar developers successfully challenged patents on trastuzumab, and adalimumab biosimilars gained market entry in 2018 following litigation, even with active dose regimen patents.35 This indicates that while biosimilar developers face substantial hurdles from post-basic patent filings, these hurdles are surmountable, with many cases being won by biosimilar developers or leading to settlements.35
B. Canada
Canada’s patent litigation landscape for biosimilars also presents unique challenges. Recent cases, such as the litigation involving Amgen’s eculizumab biosimilar (Bekemv) and Alexion’s Soliris, illustrate the dynamics. In May 2025, Canada’s Federal Court upheld Alexion’s Soliris patent (no. 2,645,810), rejecting Amgen’s invalidity challenges based on anticipation and obviousness.36 The court found that Amgen’s biosimilar infringed claims 1 and 2 of Alexion’s patent, which encompass eculizumab.37 Consequently, an injunction was issued against Amgen, barring the Canadian launch of Bekemv until the patent’s expiration in March 2027.36 The court also ordered Amgen to deliver up or destroy any infringing eculizumab product.37
The Canadian regulatory scheme for follow-on biologicals requires high similarity in quality, with comparability/equivalence studies based on ICH guidances.38 In Canada, a generic/subsequent entry biologic (SEB) applicant may allege that a listed patent is invalid or will not be infringed. If the patent holder files a prohibition order within 45 days, it triggers litigation, during which the Minister may not grant a Notice of Compliance (NOC) to the SEB applicant.38 The Federal Court can prohibit the Minister from granting an NOC until patent expiry if the SEB’s allegations are not justified.38 Innovators can also bring a patent infringement action, or SEB applicants can bring an action to impeach the patent or make a counterclaim for invalidity when sued for infringement.38 While it was once unclear if an infringement suit could be launched without an NOC or product launch, recent developments suggest a patentee may be able to maintain a counterclaim of infringement if the SEB attempts to impeach based on non-infringement.38
C. Japan
Japan’s patent linkage process for generics and biosimilars allows innovator-patent holders to voluntarily provide relevant patent information about active pharmaceutical ingredients to regulatory authorities.39 This system can lead to disputes, as exemplified by the case involving Samsung Bioepis and Bayer HealthCare concerning aflibercept. Samsung sought a preliminary injunction to prevent Bayer from providing information to the Ministry of Health, Labour and Welfare (MHLW) alleging infringement of a Bayer patent, arguing it constituted unfair competition.39
In Japan, a patentee or an exclusive licensee may file an infringement action seeking injunction and damages.40 A sole non-exclusive licensee may file for damages but not an injunction.40 Defendants in infringement litigation may raise an invalidity defense or initiate an invalidity trial before the Japan Patent Office (JPO).40 The standing requirement for an invalidity trial is broadly construed, met if a petitioner’s future business conflicts with the patent.40 Japan also applies the Doctrine of Equivalents (DoE) with five requirements, and damages can be presumed based on marginal profit or reasonable royalty.40 Japan’s regulatory scheme for follow-on biologicals emphasizes highly similar quality based on comparability/equivalence studies.38
V. Key Aspects of Biosimilar Patent Litigation
Biosimilar patent litigation involves a complex interplay of legal strategies, scientific evidence, and economic considerations for both originator companies and biosimilar developers.
A. Common Claims by Originator Companies
Originator companies, also known as reference product sponsors (RPSs), frequently assert various claims to protect their intellectual property and market exclusivity. A common type of claim made by originator companies in biosimilar patent litigation relates to manufacturing processes.41 This is because manufacturing processes are crucial for consistently producing safe and effective biologics and biosimilars, and biologic manufacturing processes tend to be covered by many patents and a wide array of intellectual property.41 Unlike small-molecule drugs, manufacturing patents for biologics are not listed in the FDA’s Orange Book, making their identification and challenge more complex.41 Most biosimilar intellectual property (IP) litigation to date has involved manufacturing patents.41
Beyond manufacturing processes, originator companies routinely bring allegations of irreparable harm.41 This claim posits that the market entry of a biosimilar would cause significant and irreversible damage to the originator’s market share, pricing power, and goodwill.43 Courts, however, do not take a uniform approach to these allegations, as the existence and irreparability of harm are contextually dependent and require intensive inquiry into the facts of each case.41 This necessitates a rigorous analysis of sales data, forecasts, market trends, and consumer preferences, often supported by expert opinions, to accurately quantify potential damages or support claims of commercial success.41
Originators also assert claims related to active pharmaceutical ingredients (API), composition of matter, and treatment methods, which have been found to correlate with longer market launch delays for biosimilars.7 These types of patents protect the core aspects of the drug and its therapeutic use, making them formidable barriers to biosimilar entry.7
B. Common Defenses by Biosimilar Developers
Biosimilar manufacturers employ several key defense strategies in patent litigation to challenge originator patents and facilitate market entry.
1. Patent Invalidity Arguments
A primary defense strategy for biosimilar manufacturers is to argue that the asserted patents are invalid.6 This invalidity defense can be based on several grounds:
Prior art: Challenging patents based on existing publications, public disclosures, or earlier inventions that predate the patent in question.5 The argument is that the claimed invention was already known or described before the patent application was filed.
Obviousness: Arguing that the patented invention would have been obvious to a person of ordinary skill in the art (POSA) at the time of the invention, given existing knowledge and prior art.5 This defense contends that the invention lacked the necessary inventive step.
Lack of enablement/written description: Challenging patents that fail to provide sufficient disclosure or enablement to allow a POSA to make and use the invention without undue experimentation.5 This defense asserts that the patent specification does not adequately describe the invention or how to practice it.43
Regulatory approvals can significantly impact patent validity challenges, as the FDA’s review process may reveal prior art or other information that can be used to challenge existing patents.5
2. Non-Infringement Arguments
Biosimilar developers also argue non-infringement, contending that their product or manufacturing process does not fall within the scope of the originator’s patent claims.6 This involves a two-step analysis: first, the court interprets the patent claims to determine their scope and meaning (claim construction), and then compares the accused biosimilar product to the construed patent claims to determine whether infringement has occurred.5
A key aspect of infringement arguments in biosimilar litigation revolves around the concept of “high similarity” required for regulatory approval.44 If a biosimilar product claims and proves high similarity to the reference product in aspects like active substance, dosage, route of administration, and formulation, it is considered highly likely to infringe patents covering those innovative elements, creating a “presumption of patent infringement”.44 To assess infringement, courts may order examination of the biosimilar’s dossier.44
A common defense strategy against infringement claims is the “carve-out” of patented features from the biosimilar’s Summary of Product Characteristics (SmPC).44 This involves omitting information directly related to patented indications or dosage regimens from the label.35 The EMA officially allows for such deletions for marketing authorization applications for biosimilar drugs.44 However, the originator can counter this by presenting evidence that the biosimilar product
inevitably uses these patented features, even if not explicitly stated on the label.44
3. “Safe Harbor” Provision
The Patent Statute includes a “safe harbor” provision (35 U.S.C. § 271(e)(1)) that protects a potential biosimilar applicant from patent infringement lawsuits if their activities are “solely for uses reasonably related to the development and submission of information to the FDA to support approval of a new drug”.31 This provision allows biosimilar developers to conduct necessary research and development, including clinical trials, without immediate risk of infringement liability.31 However, certain pre-launch activities, such as stockpiling commercial inventory, might not be protected by this safe harbor.31
C. Counterclaims by Biosimilar Applicants
Biosimilar applicants frequently employ declaratory judgment actions and counterclaims as essential tools in BPCIA litigation.15 These actions serve to challenge patent validity or assert non-infringement.15 For instance, a biosimilar applicant may bring a declaratory judgment action to seek a court’s declaration that the originator’s patent is invalid, unenforceable, or not infringed by their biosimilar product.15
In response to infringement lawsuits filed by originators, biosimilar applicants can assert counterclaims to challenge the validity or enforceability of the asserted patents.15 For example, in the litigation involving Amgen and Genentech, Amgen alleged in numerous declaratory judgment counterclaims and affirmative defenses that Genentech’s asserted patents were invalid and/or unenforceable.34 These counterclaims are a critical part of the biosimilar developer’s strategy to clear the patent landscape and facilitate market entry.15 Recent settlements, such as Amgen’s BPCIA patent infringement proceeding against Fresenius Kabi regarding its denosumab biosimilar, have resulted in the dismissal of all claims and counterclaims, highlighting the role of these legal maneuvers in reaching resolutions.46
D. Role of the Patent Trial and Appeal Board (PTAB)
The Patent Trial and Appeal Board (PTAB), established by the Leahy-Smith America Invents Act (2011), provides an alternative, more efficient pathway for challenging the validity of patents without involving an Article III court.16 The PTAB significantly influences biosimilar patent litigation strategies by offering a powerful forum for challenging patent validity, thereby accelerating market entry and dismantling “patent thickets”.2
1. Accelerating Market Entry and Dismantling Patent Thickets
The PTAB offers biosimilar applicants a strategic advantage in accelerating market entry. The Sandoz v. Amgen decision, which confirmed the optionality of the BPCIA patent dance, allows biosimilar applicants to bypass the information exchange entirely and provide their mandatory 180-day notice of commercial marketing at any time, even before FDA approval.2 This strategic maneuver can expedite litigation and accelerate market entry by collapsing traditional timelines.2 By strategically filing PTAB challenges, biosimilar manufacturers can proactively address and potentially clear patent hurdles
before becoming entangled in costly district court litigation, providing significant leverage in the broader patent dispute.2
Originator biologics are often protected by “patent thickets”—dense webs of multiple patents covering various aspects of the product, designed to extend market exclusivity and deter competition.2 PTAB challenges, particularly Inter Partes Reviews (IPRs) and Post-Grant Reviews (PGRs), are highly effective tools for biosimilar companies to “winnow these thickets” prior to, or in parallel with, district court litigation.2 By systematically challenging and invalidating individual patents or claims within the thicket, biosimilar developers can achieve clearer “freedom to operate,” reducing overall legal risk and market entry costs.2 PGRs are particularly popular for challenging biologic registrations at the PTAB due to their broader scope, allowing for “description attacks” on broad specifications common in biologic patents.2
2. Strategic Timing and Interplay with Preliminary Injunctions
Effective biosimilar strategy involves precise synchronization between PTAB challenges and BPCIA litigation.2 Biosimilar applicants often consider filing IPR or PGR petitions well in advance of, or concurrently with, the BPCIA patent dance, especially if they plan to shorten the dance or provide an early notice of commercial marketing.2 The optimal timing aims for a PTAB final written decision to be issued around the time the company anticipates being sued in district court, allowing PTAB findings to potentially influence or pre-empt district court proceedings.2 Filing PTAB petitions early in parallel litigation, ideally before the statutory one-year bar date for IPRs and prior to a scheduling conference or trial date in district court, helps avoid discretionary denials by the PTAB.2
Preliminary injunctions are critical in biosimilar litigation, often determining immediate market entry.2 Reference product sponsors frequently seek these injunctions to prevent biosimilar launch until patent validity and infringement are resolved.2 PTAB challenges can significantly undermine an originator’s ability to secure a preliminary injunction.2 The PTAB’s institution of an IPR against a patent can raise a “substantial question of validity,” making it less likely for a district court to find that the originator has a “likelihood of success on the merits”—a key factor for granting a preliminary injunction.2 This can lead to more favorable settlements for biosimilars or enable “at-risk launches” with a reduced likelihood of being enjoined.2
3. Procedural Advantages and Risks
PTAB procedures offer significant advantages over traditional federal court litigation, being consistently faster and substantially less expensive.2 While federal court patent litigation can take years and millions of dollars, PTAB proceedings typically incur legal costs in the hundreds of thousands.2 IPRs and PGRs are statutorily mandated to reach a final written decision within one year of institution, with a possible six-month extension.2 The PTAB uses a “preponderance of the evidence” standard to invalidate patents, a lower burden of proof than the “clear and convincing evidence” standard in federal courts, making invalidation comparatively easier.2 PTAB challenges also do not require formal “standing,” allowing any person (other than the patent holder) to petition, regardless of whether they have been sued or threatened.2
Despite these advantages, PTAB challenges carry risks. Statutory estoppel can prevent a losing petitioner from reasserting invalidity arguments in subsequent court proceedings that they “raised or reasonably could have raised” during the PTAB trial.2 The interpretation of “reasonably could have raised” is complex and often litigated.2 The USPTO’s new bifurcated approach for IPR and PGR petitions, implemented in March 2025, includes a preliminary assessment of discretionary denial factors, potentially increasing the likelihood of denials, especially if there is ongoing parallel district court litigation.2 This necessitates early and precise filings to mitigate the risk of discretionary denial.2 Proposed USPTO fee changes also impact filing strategies, with increased fees for IPR requests and exceeding word limits.2
E. Role of Scientific Evidence
Scientific evidence is crucial in proving biosimilarity, which, in turn, has a significant impact on patent litigation.6 To establish biosimilarity, manufacturers must conduct a comprehensive comparability exercise involving a series of analytical, nonclinical, and clinical studies.4
These studies include:
Analytical studies: These compare the molecular structure, purity, and potency of the biosimilar and the reference product.6 This highly sensitive testing aims to determine the precise profile of the drug to be copied.4
Nonclinical studies: These compare the pharmacokinetics (PK), pharmacodynamics (PD), and toxicity of the biosimilar and the reference product.6
Clinical studies: These compare the safety, efficacy, and immunogenicity of the biosimilar and the reference product.6 Biosimilar firms must conduct costly and lengthy Phase 3 trials, which typically take around 4.6 years to complete, to show that their products are similar in safety, purity, and potency.4
However, demonstrating biosimilarity presents several scientific challenges due to the inherent variability and complexity of biologic products.6 Analytical challenges arise because biologics are complex molecules, making it difficult to develop analytical methods that can accurately compare the biosimilar and reference product.6 Clinical variability in biologic products also makes it challenging to prove clinical equivalence.6 Furthermore, demonstrating a similar immunogenicity profile for the biosimilar compared to the reference product can be difficult, as biologics can trigger an immune response that affects safety and efficacy.6
In the context of patent litigation, expert testimony is vital for establishing biosimilarity, infringement, or invalidity.6 Experts in biochemistry, pharmacology, and clinical medicine provide an objective and scientific assessment of the data and evidence presented.6 Their insights into the comparability exercise help determine whether the biosimilar is highly similar to the reference product.6 Expert testimony can also be used to explain complex technical issues related to biologic products and their manufacturing processes, provide insight into patent claim interpretation, and support or challenge the validity and enforceability of patents.12
Regulatory decisions, such as the FDA’s approval of a biosimilar, also significantly impact patent litigation.5 FDA approval can serve as evidence that the biosimilar is safe and effective, which is relevant to patent litigation.5 Additionally, the FDA’s labeling decisions can influence the scope of patent claims and the potential for infringement.5 The FDA dossier, containing comprehensive scientific and clinical data, is a key piece of scientific evidence that may be shared during litigation.4
F. Patent Enforceability and Misuse
The enforceability of patents is a critical factor in biosimilar litigation, often complicated by strategies employed by originator companies. Biologics are heavily protected by extensive patent portfolios, covering everything from the manufacturing process to the final product.14 These patents are intended to allow originator companies to recoup their significant R&D investments.10 However, the introduction of biosimilars has led to a surge in patent litigation as originator companies seek to protect their intellectual property rights.6
A significant challenge arises from “patent thickets,” which are dense webs of multiple, often overlapping, patents designed to extend market exclusivity and deter competition.7 These thickets can include dozens or even hundreds of patents directed toward the same product, covering various aspects such as composition, dosing, and devices.8 For example, AbbVie’s Humira was protected by a 130-patent thicket, delaying biosimilar entry until 2023 despite the original patent expiring in 2016.50 These expansive patent portfolios introduce uncertainty for biosimilar manufacturers, who must invalidate or design around all patents to avoid litigation risk.4 The sheer number of patents asserted by brands, ranging from 11 to 65 per product for recently approved biosimilars, highlights the scale of this challenge.49
“Evergreening” practices, where minor modifications lead to secondary patents that unduly prolong market dominance, are also a concern.10 These secondary patents, while generally considered weaker and invalidated at a higher rate than primary patents, still must be challenged and revoked before biosimilars can enter the market free from risk.4 The scale and timing of patenting practices, particularly the spike in patents with terminal disclaimers as 12-year statutory exclusivity periods end, suggest that biologic firms may use them to strengthen barriers to biosimilar entry.8 Terminal disclaimers link the expiration of a later-filed patent to an earlier one, but still require biosimilar firms to contest or design around these new claims.8
Allegations of patent misuse or anticompetitive conduct are also common in biosimilar litigation. This can involve attempts by patent holders to abuse their exclusive rights by illegally obtaining or extending a patent in violation of antitrust laws.51 Examples include “pay-for-delay” agreements, where brand-name drug manufacturers conspire with generic or biosimilar manufacturers to keep less expensive alternatives off the market.51 Other strategies employed by incumbent manufacturers to delay or exclude competition include exclusive agreements for API supply and restricted distribution.52 Such practices are seen as chilling competition by discouraging competitors due to the exorbitant cost of litigating meritless patents.9 The Association for Accessible Medicines (AAM) and its Biosimilars Council advocate for legislative solutions to address these abuses, such as capping the number of asserted patents and permitting procompetitive patent settlements.9
Inequitable conduct, sometimes referred to as the “atomic bomb of patent law,” can result in a patent being held unenforceable if it is proven that material information was withheld from the U.S. Patent and Trademark Office (USPTO) with an intent to deceive during patent prosecution.53 While less common, such allegations can arise in biosimilar litigation, as seen in cases involving transgenic mice patents.53
VI. Factors Influencing Litigation Outcomes
Predicting the outcome of biosimilar patent litigation requires a nuanced understanding of several interconnected factors, ranging from regulatory decisions and patent strength to competitive intelligence and economic implications.
A. Regulatory Decisions
Regulatory approvals and decisions by bodies like the FDA and EMA play a critical role in shaping patent disputes.5 The approval of a biosimilar by a regulatory agency can have significant implications for patent infringement and validity challenges.5 For example, an FDA finding that a biosimilar is “highly similar” to the reference product may be relevant to a patent infringement analysis, indicating that the biosimilar might not infringe certain patents covering the reference product.13 Conversely, FDA approval can also be used as evidence of infringement if the biosimilar is deemed to be too similar in a patented aspect.5
Regulatory approvals also impact patent validity challenges. The FDA’s review process may reveal prior art or other information that can be used to challenge existing patents.5 Labeling decisions made by the FDA can affect the scope of patent claims and the potential for infringement.6 For instance, the EMA officially allows for the deletion of information directly related to patented indications from the Summary of Product Characteristics (SmPC) for biosimilar marketing authorization applications, which can be a defense strategy against infringement claims.44 However, originators may still argue that the biosimilar inevitably uses these patented features.44
The evolving regulatory frameworks and guidance, especially regarding interchangeability, can further influence litigation strategies and outcomes.6 For example, the FDA’s revised guidance in 2024 on additional pathways to support interchangeability could increase the number of interchangeable biosimilars, potentially leading to more complex litigation related to substitution practices.41
B. Patent Strength Assessment
Assessing the strength of existing patents is a critical component of a biosimilar developer’s strategy. This involves a comprehensive analysis of the patent landscape to identify potential risks and opportunities.12
Key methodologies and considerations include:
Freedom to Operate (FTO) Analysis: This foundational step involves a detailed examination of the patent landscape surrounding the reference biologic to identify any patents that might restrict the commercialization of the biosimilar.54 This analysis extends beyond the primary patent of the biologic to include secondary patents covering manufacturing processes, formulations, or specific therapeutic uses.54 Understanding these constraints helps in strategizing ways to navigate or challenge potential patent barriers.54
Prior Art Search and Validity Assessment: This involves reviewing prior art to identify potential grounds for invalidity, evaluating the patent’s written description and enablement requirements, and assessing its compliance with statutory requirements such as obviousness and novelty.5 This detailed assessment of the strengths and weaknesses of existing patents is crucial for determining the likelihood of success in patent disputes.54
Innovating Around Existing Patents: If an existing patent appears too robust to challenge, an alternative strategy is to innovate around it.54 This could involve developing a new production method or a novel formulation that does not infringe on existing patents.54 This not only circumvents existing patents but can also strengthen the biosimilar developer’s own patent portfolio.54
The complexity of biologic products and their manufacturing processes gives rise to a multitude of patents, making patent disputes inevitable and challenging to navigate due to the uncertainty surrounding the interpretation of patent claims.12
C. Competitive Intelligence and Patent Data Analytics
Competitive intelligence (CI) is the systematic collection, analysis, and application of data about competitors, market trends, and regulatory changes to inform strategic decision-making in the pharmaceutical industry.56 In the biosimilar market, patent data analytics is a crucial component of CI, offering unprecedented visibility into the future competitive landscape and enabling more informed strategic planning.57
By systematically tracking, analyzing, and interpreting legal proceedings related to pharmaceutical patents, companies can gain crucial insights into the timing and likelihood of biosimilar entry, potential market disruptions, and competitive threats.57 This involves monitoring intellectual property filings to identify potential competitive threats or licensing opportunities.56
DrugPatentWatch, for instance, provides relevant features and data points for biosimilar competitive intelligence.50 These include insights into legislative reforms, such as the Affordable Prescriptions for Patients Act (S.150), which caps patent assertions to 20 per biologic product and requires patent quality filters for BPCIA litigation.50 These reforms are projected to reduce affected drug prices by 20% through accelerated biosimilar entry.50
Strategic litigation innovations are also tracked, such as the effectiveness of Phase 3 preclearance protocols. Data indicates that 92% of Phase 3 trial biosimilars generate sufficient data for early patent challenges, and early litigation reduces market entry delays by 4.8 times compared to post-approval disputes.50 Outcome analysis provides a clear picture of the impact of litigation results on market entry and penetration:
Table: Biosimilar Litigation Outcomes and Market Entry/Penetration
Litigation Result
Avg. Entry Delay
Market Penetration Rate (within 12-18 months)
Biosimilar Win
2.3 years
84% within 12 months
Settlement
2.5 years
63% within 18 months
Loss
16.5 years
22% after 5 years
50
Global harmonization efforts, such as the U.S. adopting EU-style patent challenge timelines through pre-Phase 3 patent validity reviews and IPR acceleration protocols, are also relevant data points.50 Emerging defense strategies against patent thickets, including terminal disclaimer audits, AI-powered prior art analysis (which can identify weak patents 82% faster), and manufacturing process leapfrogging (where 68% of recent biosimilars bypass originator methods), are also tracked.50 These advanced manufacturing technologies can circumvent 63% of process patents, and AI tools can cut patent clearance costs by $2.8 million per application.50
By categorizing litigation by patent type and tracking historical outcomes, analysts can develop increasingly refined predictions for specific products and therapeutic areas.57 This data-driven approach allows companies to identify specific claim construction patterns, analyze appeal success rates for different invalidation arguments, and integrate international patent challenge data, all of which contribute to more accurate predictions of biosimilar entry and market impact.57
D. Economic Considerations
The economic implications of biosimilar patent litigation are significant, affecting originator companies, biosimilar manufacturers, and the broader healthcare system.6
For originator companies, a biosimilar’s approval and market entry can lead to lost revenue and a decrease in market share.6 The introduction of biosimilars often results in significant pricing pressure, forcing originators to reduce their prices to remain competitive.6 The value of the intellectual property at issue and its impact on the economic landscape are crucial considerations in litigation.41 Courts assess the commercial success of a drug and damages from alleged infringement through rigorous analysis of sales data, forecasts, market trends, and consumer preferences.41
For biosimilar manufacturers, successful litigation outcomes can lead to market share gains and contribute to substantial cost savings for patients and healthcare systems.6 Biosimilars can increase access to life-saving medicines for patients who cannot afford the originator product and promote competition in the pharmaceutical industry, leading to lower prices and improved patient outcomes.6 The cost savings associated with biosimilars can be substantial, with estimates suggesting billions in savings for healthcare systems.6
The economics of biosimilar IP litigation share commonalities with generic pharmaceutical drug litigation, but the regulatory frameworks differ, such as the BPCIA’s patent dance and longer exclusivity periods for biologics.41 Manufacturing patents are relatively more likely to be asserted in biosimilar IP litigation due to their importance in consistently producing safe and effective biologics and the extensive IP covering these processes.41 Litigants also advance claims of anticompetitive effects related to the timing and extent of biosimilar entry, some of which are specific to biologics and biosimilars.41 These economic considerations, including interchangeability, marketing efforts, and rebating strategies, are crucial for informing legal strategies and strengthening economic arguments before courts.41
VII. Strategic Implications of Litigation Outcomes
The outcomes of biosimilar patent litigation have profound strategic implications, influencing market entry, pricing dynamics, and the broader landscape of pharmaceutical innovation and competition.
A. Impact on Market Entry and Pricing
Patent litigation directly affects the timing of biosimilar market entry. Protracted litigation, particularly when litigated to a final conclusion with appeals, can last for several years following FDA approval of the biosimilar, leading to delayed launch long after the expiry of the primary patent.4 This delay prevents lower-cost biosimilars from entering the market in a timely fashion, undermining the BPCIA’s goal of expediting commercialization and enhancing market access.4
The ability to “pre-clear” patents through the patent dance and associated litigation, or to launch “at risk” (where a biosimilar company launches before all litigation is resolved, risking significant damages if found to infringe valid patents), are key strategies for biosimilar firms to accelerate market entry.4 Settlements are a common outcome in BPCIA litigation, with 67% of terminated cases ending in settlement or stipulated voluntary dismissals.17 These settlements often accelerate patient access to generic and biosimilar medicines by, on average, more than five years before patent expiration, with some cases accelerating entry by over a decade.18
The entry of biosimilars significantly impacts pricing. Biosimilars typically cost less than their reference biologics, with average savings ranging from 15% to 35% off the retail price.22 This competitive pricing can lead to substantial cost reductions for patients, payers, and healthcare systems.3 Studies demonstrate that biosimilars can be 15-30% less expensive than their reference drugs, offering significant cost-saving opportunities.3 For example, a network of community oncology practices saved approximately $47 million in six months through biosimilar substitution.3 The more generic and biosimilar versions available, the greater the potential savings.22 However, systemic barriers, such as PBM influence and certain market strategies, can impede biosimilar adoption and limit the full realization of cost-saving potential.3
B. Impact on Pharmaceutical Innovation
The patent litigation landscape for biosimilars creates a dynamic tension between incentivizing innovation and promoting competition. Originator companies rely on robust patent protection and extended exclusivity periods to recoup their enormous R&D investments, which can exceed billions of dollars.10 This protection is crucial for fostering the development of novel, life-saving biologic therapies.5
However, overly expansive patent portfolios, particularly “patent thickets” and “evergreening” practices, can unduly prolong market dominance and delay biosimilar entry, thereby limiting competition.9 This can hinder the very competition that drives down prices and increases patient access.9
The introduction of biosimilars itself has spurred innovation within the pharmaceutical industry.5 Originator companies are incentivized to develop new and improved products, including next-generation biologics or “biobetters,” to maintain their competitive edge in the face of biosimilar competition.5 This dynamic encourages continuous investment in research and development to enhance existing products or create novel therapies, benefiting patients through a broader array of treatment options.5 Therefore, while litigation can be a barrier, it also acts as a catalyst for ongoing innovation.
C. Competitive Advantage
Successful navigation of biosimilar patent litigation can provide a significant competitive advantage for both originator companies and biosimilar developers.
For originator companies, successfully defending patents, particularly primary patents and key secondary patents, can maintain market exclusivity and protect revenue streams for extended periods.4 Winning patent litigation cases or securing favorable settlements with delayed biosimilar entry dates allows originators to maximize their return on investment before significant competition emerges.59 Strategic use of the BPCIA’s framework, including the patent dance, enables originators to protect their intellectual property rights effectively.2
For biosimilar developers, successful patent challenges and strategic litigation maneuvers are crucial for gaining market access and establishing a competitive presence.13 By invalidating weak or invalid patents, or by designing around existing patent protections, biosimilar firms can clear the path for their products.4 The ability to launch a biosimilar, especially “at-risk” or through early settlements, provides a first-mover advantage and allows for earlier capture of market share.33 This is particularly evident in the European market, where biosimilar developers have often won challenges against secondary patents, leading to earlier market entry.35 The strategic use of PTAB challenges, for instance, can provide a more efficient and cost-effective route to invalidate patents, thereby reducing overall legal risk and market entry costs.2
The ability of biosimilar companies to demonstrate “high similarity” to the reference product is not only a regulatory requirement but also a strategic asset in patent disputes, as it can be leveraged to argue non-infringement or challenge the scope of originator patents.13 Ultimately, effective strategies in biosimilar patent litigation, informed by deep understanding of regulatory frameworks and technical expertise, are critical for navigating the complexities and achieving market goals.13
VIII. Notable Biosimilar Patent Litigation Case Studies
Several high-profile biosimilar patent litigation cases illustrate the complexities and strategic dynamics of this landscape.
A. Humira (adalimumab)
Humira (adalimumab), AbbVie’s blockbuster anti-inflammatory drug, has been central to extensive biosimilar patent litigation. AbbVie built a formidable “patent thicket” around Humira, comprising over 130 patents, which effectively delayed biosimilar entry in the U.S. until 2023, despite the original patent expiring in 2016.50 This strategy involved pursuing overlapping patents to deter competitors.59
Despite challenges and allegations of “unclean hands” (e.g., by Boehringer Ingelheim, which accused AbbVie of pursuing overlapping patents), most biosimilar developers, including Amgen, Pfizer, and Mylan, ultimately settled with AbbVie for U.S. entry in 2023.59 For instance, AbbVie resolved U.S. litigation with Boehringer Ingelheim in May 2019, granting a non-exclusive license beginning July 1, 2023, with Boehringer paying royalties and acknowledging patent validity.63 These settlements resolved all Humira-related patent litigation in the U.S., providing access for biosimilar manufacturers while securing extended exclusivity for AbbVie.59 In Europe, Humira biosimilars captured 15% of the market within four months of launching, with predictions of reaching 50% within a year.59
B. Enbrel (etanercept)
Amgen, the reference product sponsor for Enbrel (etanercept), has successfully defended its patents against biosimilar challenges. In August 2019, the U.S. District Court for the District of New Jersey ruled in Amgen’s favor on the validity of two patents (U.S. Patent Nos. 8,063,182 and 8,163,522) that describe and claim Enbrel and methods for making it.60 Sandoz, the biosimilar applicant, had acknowledged that its etanercept biosimilar infringed seven claims of these patents, with the trial proceeding solely on Sandoz’s challenges to their validity.60 The court found that Sandoz had not met its burden to prove these claims invalid, and a preliminary injunction remained in place.60
This decision was affirmed by the United States Court of Appeals for the Federal Circuit in July 2020, upholding the validity of the Enbrel patents and the injunction against Sandoz’s infringement.61 A final judgment and permanent injunction were entered in October 2019, prohibiting Sandoz from making, using, importing, selling, or offering for sale its etanercept product.61 These outcomes underscore the strength of Amgen’s patent rights and their ability to protect market exclusivity for Enbrel.
C. Remicade (infliximab)
Litigation involving Remicade (infliximab) has included significant antitrust claims related to biosimilar competition. In July 2021, Johnson & Johnson (J&J) and Pfizer settled an antitrust suit regarding Remicade after nearly four years of litigation.64 Pfizer had alleged that J&J violated the Sherman Act and Clayton Act by entering into de facto exclusivity agreements with insurers and providers of Remicade.64 These agreements allegedly conditioned discounts and rebates for Remicade on promises to eliminate or drastically reduce dealings with infliximab biosimilars, including Pfizer’s Inflectra.64 While the settlement terms were confidential, J&J stated that prices for Remicade and other infliximabs had subsequently declined since biosimilars were introduced, indicating the impact of competition.64
In a separate Canadian case, the Federal Court reinstated a decision that a Remicade new use patent (Canadian Patent No. 2,261,630) for the use of infliximab with methotrexate for rheumatoid arthritis was valid and infringed by Hospira’s biosimilar Inflectra.65 This case highlighted complex issues of anticipation, obviousness, and enablement in patent validity challenges.65
D. Rituxan (rituximab)
Rituxan (rituximab) is an older molecule, with its first approval in the U.S. in November 1997, making it one of the first monoclonal antibodies to face biosimilar competition.66 Several rituximab biosimilars have entered the U.S. market, including Truxima (Teva and Celltrion, launched May 2020), Rituxience (Pfizer, launched January 2020), and Riabni (Amgen and Allergan, approved December 2020).66
In April 2024, Genentech, Hoffmann-La Roche, and Biogen settled patent infringement claims against Dr. Reddy’s Laboratories and Fresenius Kabi regarding Dr. Reddy’s proposed rituximab biosimilar.66 The terms of this settlement were not publicly disclosed.66 The absence of publicly identified patents for Rituxan derived from brand-side litigation or company disclosures on DrugPatentWatch suggests that settlements or other mechanisms may have resolved disputes without extensive public patent listings.67
E. Eylea (aflibercept) and Soliris (eculizumab)
Recent and ongoing cases involving Eylea (aflibercept) and Soliris (eculizumab) further underscore the dynamic nature of biosimilar patent litigation.
For Eylea, Regeneron, the originator, has actively sought to prevent the marketing of biosimilar versions. In a notable case, the Federal Circuit affirmed a district court’s decision to grant a preliminary injunction against Samsung Bioepis (SB) to prevent the sale of its Eylea biosimilar.43 The court found that Regeneron was likely to succeed on the merits of its patent infringement claims and that SB had not presented a substantial invalidity defense, particularly regarding obviousness-type double patenting or lack of written description.43 The court also found that Regeneron would suffer irreparable harm from market share loss and price erosion if the biosimilar launched.43 This decision reinforced the strength of Regeneron’s patent rights and the importance of detailed patent specifications.43 As of early 2024, Eylea had five pending lawsuits, a number of pending IPRs, and at least five pending aBLAs, indicating it remains a drug to watch for market impact.62
For Soliris (eculizumab), Alexion, the originator, has also engaged in litigation to protect its market. As discussed in Section IV.B, Canada’s Federal Court upheld Alexion’s Soliris patent against Amgen’s challenges, leading to an injunction delaying Amgen’s biosimilar launch until March 2027.36 In the U.S., both Samsung Bioepis and Amgen reached settlements with Alexion in relation to their eculizumab biosimilars, with two biosimilars launching in early 2025.37 This followed a class action complaint alleging Alexion unlawfully delayed biosimilar competition by misusing its patents.37 Samsung Bioepis had provided its 180-day notice of commercial marketing in July 2023, indicating a potential “at-risk” launch after FDA approval.62
Another case to watch is Tysabri (natalizumab), which has ongoing litigation related to a Sandoz biosimilar, Tyruko, approved by the FDA in August 2023. A preliminary injunction was denied in June, and Sandoz expressed plans to launch at risk in the first half of 2024, marking the first biosimilar launch for Tysabri, approved almost 20 years prior.62 These cases collectively highlight the ongoing and evolving nature of biosimilar patent litigation, with significant implications for market access and competition.
IX. Current Trends and Future Outlook
The biosimilar market is dynamic, shaped by evolving trends in market growth, regulatory frameworks, expert opinions, and litigation statistics.
A. Market Trends (2024-2025)
The global biosimilars market is projected to continue its robust growth, reaching an estimated value of US34.8billionin2024andexpandingtoUS93.1 billion by 2030, with a CAGR of 17.8%.1 As of 2025, the market is valued at approximately USD 40.36 billion, with expectations to reach USD 175.99 billion by 2034.69
Regional Dominance and Growth:
Europe currently dominates the global biosimilars market, holding an estimated 40.8% share in 2024.1 This is attributed to its robust healthcare system, rising disease prevalence, supportive regulatory framework, and swift adoption of biosimilars.1 Europe’s market size is estimated at USD 15.32 billion in 2025.69
The Asia-Pacific region is experiencing rapid growth, with a projected CAGR of 20.3% from 2024-2030.1 Valued at USD 2.86 billion in 2025, it is forecasted to grow at a CAGR of 31.6% through 2033, driven by increased investments in R&D, demand for affordable treatments, and an aging population.1 Countries like India and China are investing in manufacturing and regulatory modernization.69
The U.S. biosimilars market is expected to reach USD 22.59 billion in 2025, with a CAGR of 17.1% through 2034.69 This rapid growth follows a significant increase in market share post-2019, driven by the expanding FDA approval process.69
Key Therapeutic Areas:
Monoclonal antibodies (mAbs) lead the biosimilars market, capturing a 56% share in 2024 due to their widespread application in treating conditions like cancer, rheumatoid arthritis, cardiovascular issues, and multiple sclerosis.1 Oncology biosimilars, such as trastuzumab, bevacizumab, and rituximab, have achieved over 80% molecule volume share within three years of launch.69 The oncology application is the largest segment, with a 42.6% share in 2024, and is anticipated to experience the fastest growth (CAGR of 18.4% from 2024-2030) due to increasing global cancer rates.1
The autoimmune diseases segment is the second largest, with a 22.6% share in 2024, driven by the rising prevalence of conditions like rheumatoid arthritis and psoriasis.1 Adalimumab biosimilars are projected to drive major cost savings and wider patient access starting in 2025.69
The erythropoietin (EPO) segment is anticipated to record the fastest growth with a CAGR of 19.2% during 2024-2030, fueled by its increasing use in managing anemia and rising regulatory approvals.1
Insulin biosimilars are a rapidly growing segment driven by the global diabetes burden, with insulin glargine and adalimumab biosimilars already securing interchangeability status.69 The next wave of competition is expected for drugs like Ozempic (semaglutide) and Stelara (ustekinumab) by 2025-2026.69
Interchangeable Biosimilars and Patient-Centric Innovations:
Interchangeable biosimilars are expected to accelerate adoption, particularly in the U.S., as more products receive FDA approval for substitution without prescriber intervention, boosting physician and patient confidence.69 Beyond intravenous (IV) administration, the market is seeing a shift towards patient-centric innovations, such as self-injectables and subcutaneous formulations, which enhance patient convenience and reduce healthcare burdens.69
B. Regulatory and Legislative Developments
Regulatory and legislative efforts are actively shaping the biosimilar landscape to address market barriers and promote competition.
Proposed Reforms: Congress is considering numerous proposals to reform the patent system and accelerate biosimilar entry.9 These include:
Capping the Number of Asserted Patents: Legislation like H.R. 3269, the ETHIC Act, proposes restricting brands to asserting a single patent out of a terminally-disclaimed family, ensuring that obvious variants of the same patent claims cannot continuously be asserted against biosimilar manufacturers.9 The Affordable Prescriptions for Patients Act (S.150) caps patent assertions to 20 per biologic product, with exemptions for actively used manufacturing process patents and requirements for patent quality filters.50
Permitting Procompetitive Patent Settlements: There is legislative consideration to ensure that patent litigation settlements remain a viable option, as disincentivizing settlements could force biosimilar manufacturers to bear the extraordinary cost and burden of challenging brand patents through full litigation.49 A report based on IQVIA Institute research concluded that patent settlements have accelerated patient access to generic and biosimilar medicines by, on average, more than five years before patent expiration.18
Providing a Statutory Safe Harbor for Labeling Carve-outs: Congress is urged to enact legislation that provides a statutory safe harbor for labeling carve-outs, allowing biosimilar developers to omit patented indications from their labels.49
Accelerating the Patent Dance: Proposals suggest allowing the initiation of patent litigation earlier, for instance, at the point when a developer has a Type III development meeting with FDA, rather than waiting for the aBLA filing. This would accelerate the timeline of litigation and permit biosimilars to be marketed sooner.9
Forcing Assertion of All Relevant Patents: Legislation could compel brand drug companies to assert all relevant patents promptly, preventing them from holding patents in reserve to threaten later litigation and enabling biosimilar developers to cut through patent thickets faster.9
Executive Orders and Regulatory Body Statements:
Executive orders and statements from regulatory bodies also influence the biosimilar market. President Trump issued executive orders concerning drug access and affordability, including for biologics and biosimilars, directing the FDA to provide recommendations on how to accelerate approval of generics and biosimilars.70
Regulatory bodies like the Federal Trade Commission (FTC) are focusing on improving pharmaceutical affordability by increasing generic and biosimilar availability and promoting competition through drug formularies and benefits.52 They address anticompetitive conduct by pharmaceutical companies, including potential pay-for-delay agreements, exclusive agreements for API supply, restricted distribution, formulary design, rebating practices, and disparaging the safety and efficacy of generics and biosimilars to hinder uptake.52 The FDA has also issued guidance on interchangeability, which, while a federal authority, relies on state laws for pharmacy-level substitution.29
C. Expert Opinions
Experts in the field emphasize that while biosimilar guidelines from stringent regulatory authorities like EMA and USFDA are robust, further alignment of regulatory standards in the U.S. and EU is possible to reflect scientific progress and clinical experience.11 Global harmonization of biosimilar guidelines, based on gained developments and regulatory experience, could accelerate the development and approval process, facilitating earlier and enhanced access to safe and affordable biologics.11
There is also a view that regulatory requirements for biosimilars in emerging markets appear disproportionate to scientific advancements and accumulated knowledge.11 Experts note that biosimilar manufacturers can only initiate patent litigation to clear weak and invalid patents after submitting their Biologic License Application to the FDA, which occurs after costly clinical trials.4 This contrasts with generic drug patent clearance timelines, where litigation often occurs before primary patent expiration, allowing for quicker market entry.4 The lengthy development programs for biosimilars often lead to litigation of secondary patents after primary patent expiration.4
D. Litigation Statistics
Analysis of biosimilar litigation statistics reveals key trends. Most BPCIA litigations are ending in settlements, with 31 of 46 (67%) terminated BPCIA litigations ending in settlement or stipulated voluntary dismissals.17 This suggests a preference for negotiated outcomes over full trials.
A study investigating biosimilar market delays found that while manufacturing patents are frequently asserted, a higher proportion of composition, API, and treatment patents correlated with longer market launch delays.7 Biosimilars that lost litigation had a median market launch delay of 3571 days (approximately 9.9 years) longer than those that won or settled during litigation.7 In cases where biosimilars settled during litigation, a greater number of manufacturing, composition of matter, and treatment patents were asserted compared with biosimilars that won or lost litigation.7 This indicates that the nature of the patents asserted significantly influences the duration and outcome of disputes.
X. Conclusion
Predicting patent litigation outcomes for biosimilars is a multifaceted challenge rooted in the complex interplay of scientific, legal, and economic factors. The burgeoning global biosimilar market, driven by the imperative for more affordable biologic therapies, inevitably clashes with the extensive patent portfolios and strategic maneuvers of originator companies. This creates a landscape where patent litigation is not merely a legal formality but a central determinant of market entry, pricing, and the trajectory of pharmaceutical innovation.
The analysis underscores that while manufacturing patents are frequently asserted by originators, patents covering the active pharmaceutical ingredient, composition, and treatment methods are more strongly correlated with prolonged biosimilar market delays. This suggests that the core intellectual property protecting the drug’s fundamental nature and use presents the most significant barriers. The optional yet strategically advantageous “patent dance” under the BPCIA framework, along with the two phases of litigation, provides a structured, albeit often lengthy, mechanism for resolving these disputes.
The emergence of the Patent Trial and Appeal Board (PTAB) has significantly altered litigation strategies, offering biosimilar developers a faster and more cost-effective avenue to challenge patent validity and dismantle patent thickets. The PTAB’s ability to raise substantial questions of validity can undermine originator attempts to secure preliminary injunctions, thereby facilitating earlier market entry for biosimilars. However, the ongoing evolution of PTAB procedures and the inherent risks of estoppel require careful strategic timing and execution by biosimilar applicants.
Scientific evidence, derived from rigorous analytical, nonclinical, and clinical comparability studies, forms the bedrock of biosimilarity demonstrations and is critical in litigation. Expert testimony is indispensable for interpreting complex scientific data and its implications for patent infringement or validity. Furthermore, allegations of patent misuse and the proliferation of patent thickets highlight the need for ongoing regulatory and legislative reforms to balance intellectual property protection with the public interest in timely access to affordable medicines.
Ultimately, successful navigation of this complex landscape demands a comprehensive understanding of regulatory nuances, robust patent strength assessment, and sophisticated competitive intelligence leveraging patent data analytics. The prevalence of settlements in biosimilar litigation points to a pragmatic approach by market participants to mitigate risk and accelerate market access. As more biologics face patent expiration and regulatory frameworks continue to evolve, the strategic management of patent litigation will remain paramount for both originator companies seeking to protect their innovation and biosimilar developers striving to expand patient access and drive healthcare cost savings.
